Lexicon Pharmaceuticals, Inc.

What they do

Lexicon markets INPEFA (sotagliflozin) in the U.S. to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. It is running the pivotal Phase 3 SONATA-HCM trial of sotagliflozin in hypertrophic cardiomyopathy and is preparing to potentially resubmit an NDA for ZYNQUISTA (sotagliflozin) in type 1 diabetes. It also has pilavapadin in Phase 2 for diabetic peripheral neuropathic pain and has licensed LX9851 to Novo Nordisk for obesity and cardiometabolic disorders.

Revenue drivers

• Net product revenue (INPEFA) — U.S. sales of approved INPEFA were $680 thousand in Q2 2026 and $1.77 million in the first half of 2026, down from $1.32 million and $2.58 million in the comparable 2025 periods.
• Licensing and milestone revenue — The largest revenue line in recent periods; $20.0 million in the first half of 2026 and $27.5 million in Q2 2025, tied to the Novo Nordisk LX9851 license (a $45 million upfront plus two $10 million clinical development payments) rather than product sales.
• Royalties and other revenue — Small and early-stage at $24 thousand in the first half of 2026, reflecting royalties and other items rather than a scaled commercial stream.

Recent performance

Q2 2026 total revenue was $692 thousand versus $28.9 million in Q2 2025, as the prior-year quarter included $27.5 million of licensing and milestone revenue while Q2 2026 had none. First-half 2026 revenue was $21.8 million versus $30.1 million a year earlier, and the net loss from operations was $27.5 million in the first half. R&D expense was $30.2 million and SG&A was $19.0 million in the first six months of 2026. Full-year 2025 revenue was $49.8 million against a net loss of $50.3 million, compared with $6.0 million of revenue and a $200.4 million loss in 2024.

Strategy

Management says it is prioritizing disciplined, targeted capital allocation across the clinical programs and building early commercial planning for the late-stage pipeline. Near-term value is tied to completing SONATA-HCM, with topline data expected in Q1 2027, and resubmitting the ZYNQUISTA NDA in type 1 diabetes, which Lexicon anticipates in Q4 2026 if supported by the STENO1 safety data. For pilavapadin, the company states it lacks sufficient capital to fund Phase 3 development in DPNP on its own and is advancing third-party collaboration discussions. LX9851 development has shifted to Novo Nordisk, which began a Phase 1 study in March 2026 expected to complete in Q1 2027.

Risks

• Clinical and regulatory failure — The value of the pipeline depends on SONATA-HCM succeeding and on the FDA accepting a ZYNQUISTA resubmission, and the FDA has already issued complete response letters on that NDA in March 2019 and December 2024.
• Capital needs — The company states it does not have sufficient capital to support Phase 3 development of pilavapadin in DPNP, and failure to establish a collaboration or obtain financing could force it to delay, reduce or eliminate programs.
• Revenue concentration in licensing — Recent revenue has come from a limited number of sources, principally Novo Nordisk license and milestone payments, so quarterly results swing sharply when no milestone is recognized.
• Weak commercial product revenue — INPEFA net product revenue fell to $680 thousand in Q2 2026 from $1.32 million in Q2 2025, leaving the company dependent on pipeline and partnering outcomes rather than current sales.

Outlook

Lexicon expects SONATA-HCM topline results in Q1 2027 and anticipates resubmitting the ZYNQUISTA NDA in type 1 diabetes in Q4 2026 based on current estimated timing of STENO1 data collection. Novo Nordisk's Phase 1 program for LX9851 is expected to complete in Q1 2027, and Lexicon is eligible for a third $10 million milestone payment as early as later this year under the Novo Nordisk agreement. Viatris, the ex-U.S. ex-Europe sotagliflozin licensee, has approvals in the United Arab Emirates and Bahrain and anticipates regulatory decisions in Australia and Canada in 2026.